Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut Microbiota Composition and Plasma Metabolomic Profile Are Associated with Amyloid Pathology and Cognitive Performance in Patients with Mild Cognitive Impairment.

Nutrients·2026
Same author

A controlled-release mitochondrial protonophore attenuates early- and late-stage atheroprogression in mice.

Science translational medicine·2026
Same author

<i>Tet2</i> and <i>Jak2</i> clonal hematopoiesis do not modify murine tauopathy.

Journal of Alzheimer's disease : JAD·2026
Same author

Functional coupling between the α4 - α5 loop and allosteric site on MKP5 is a critical determinant of catalysis.

bioRxiv : the preprint server for biology·2026
Same author

Cross-dataset benchmarking of machine learning models for marine and atmospheric environmental prediction.

PloS one·2026
Same author

A decline in skeletal muscle NOX4 abrogates exercise-induced adaptive homeostasis and exacerbates biological aging.

Science advances·2026

Related Experiment Video

Updated: Jun 15, 2025

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

18.8K

miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression.

Pablo Fernández-Tussy1,2,3, Magdalena P Cardelo1,2,3, Hanming Zhang1,2,3

  • 1Vascular Biology and Therapeutics Program.

JCI Insight
|August 27, 2024
PubMed
Summary

Suppressing hepatic miR-33, a regulator of lipid metabolism, improved metabolic dysfunction-associated steatotic liver disease (MASLD) and limited liver cancer development in preclinical models.

Keywords:
Fatty acid oxidationHepatologyLiver cancerMetabolismNoncoding RNAs

More Related Videos

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice
10:04

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice

Published on: December 2, 2022

4.3K
In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
08:50

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines

Published on: April 18, 2025

365

Related Experiment Videos

Last Updated: Jun 15, 2025

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

18.8K
Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice
10:04

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice

Published on: December 2, 2022

4.3K
In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
08:50

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines

Published on: April 18, 2025

365

Area of Science:

  • Hepatology
  • Molecular Biology
  • Metabolic Disease Research

Background:

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) progression is complex and challenging to treat.
  • MicroRNAs (miRNAs) are key regulators of biological processes and potential therapeutic targets.

Purpose of the Study:

  • To investigate the role of hepatic miR-33 in MASLD progression and hepatocellular carcinoma (HCC) development.
  • To evaluate the therapeutic potential of targeting hepatic miR-33.

Main Methods:

  • Studied miR-33 levels in human and mouse MASLD liver samples.
  • Generated hepatocyte-specific miR-33 knockout (HKO) mice.
  • Assessed liver steatosis, inflammation, fibrosis, and HCC development in HKO mice.
  • Analyzed lipid metabolism, mitochondrial function, oxidative stress, and YAP/TAZ pathway activation.

Main Results:

  • miR-33 was elevated in MASLD livers.
  • miR-33 HKO improved steatosis, inflammation, and fibrosis, limiting MASH and HCC progression.
  • Hepatic miR-33 deletion reduced lipid synthesis, enhanced fatty acid oxidation, and improved mitochondrial function.
  • Reduced liver injury and lipid accumulation decreased YAP/TAZ pathway activation.

Conclusions:

  • Hepatic miR-33 plays a critical role in MASLD progression and HCC development.
  • Suppression of hepatic miR-33 is a promising therapeutic strategy for MASLD, MASH, and obesity-related HCC.